Treatment
Table 2. Common Antimicrobials Used for Chronic Oral
Antimicrobial Suppression (unless otherwise stated in texta,b)
Microorganism
Preferred Treatmenta
Alternative Treatmenta
Staphylococci, oxacillinsusceptible
Cephalexin 500 mg orally
tid or qid
OR
Cefadroxil 500 mg PO bid
Dicloxacillin 500 mg orally
tid or qid
Clindamycin 300 mg PO
qid
Amoxicillin-clavulanate
500 mg PO tid
Staphylococci, oxacillinresistant
Cotrimoxazole 1 DS tab
PO bid
OR
Minocycline or doxycycline
100 mg PO bid
Penicillin V 500 mg PO
bid to qid
OR
Amoxicillin 500 mg PO tid
Penicillin V 500 mg PO
bid to qid
OR
Amoxicillin 500 mg PO tid
Ciprofloxacin 250-500 mg
PO bid
Cotrimoxazole 1 DS tab
PO bid
Penicillin V 500 mg PO
bid to qid
OR
Amoxicillin 500 mg PO tid
B-hemolytic streptococci
Enterococcus spp.
penicillin susceptible
Pseudomonas aeruginosa
Enterobacteriaceae
Propionibacterium spp.
a
Cephalexin 500 mg orally
tid or qid
��-lactam oral therapy based
on in vitro susceptibilities
Cephalexin 500 mg orally
tid or qid
Minocycline or doxycycline
100 mg PO bid
Antimicrobial dosage needs to be adjusted based on patient's renal and hepatic function.
Antimicrobials should be chosen based on in vitro susceptibility as well as patient drug allergies,
intolerances and potential drug interactions or contraindications to a specific antimicrobial.
b
Clinical and laboratory monitoring for efficacy and safety should occur based on the clinical
judgment of the clinician caring for the patient. The possibility of prolonged QTc interval and
tendinopathy should be discussed and monitored when using fluoroquinolones. The possibility of
C. difficile colitis should also be discussed when using any antimicrobial.
12
